LONDON (Reuters)—AstraZeneca’s hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. Amgen, its partner on the project, announced late on Friday it was ending a collaboration to develop brodalumab after suicidal…
Lyme Disease Not Predictor of Long-Term Physical, Mental Health Issues
Lyme disease is often considered a cause of chronic fatigue, pain and other incapacitating symptoms. This assumption stems from analyses of patients who seek retreatment for Lyme disease. However, a new study suggests that Lyme disease is not life altering in the long term for most patients. Specifically, patients with culture-confirmed Lyme disease have similar…
Rising Costs of Biologics in the U.S. Suggest Need for Negotiation Ability
The costs of some disease-modifying therapies outpace prescription drug inflation, saddling insured patients with thousands of dollars in out-of-pocket payments and delayed or denied coverage, two new studies have shown. Disease-modifying therapies for multiple sclerosis are rising in cost five to seven times faster than inflation and cost more in the United States than in…
Bone Microarchitecture Impaired in Active Celiac Disease
Bone microarchitecture is impaired in premenopausal women with active celiac disease, a new study from Argentina shows. “This report helps us to understand how bone is affected in celiac disease: increasing bone resorption and thinning trabeculae, even losing some number of them,” Dr. María Belén Zanchetta from Instituto de Diagnóstico e Investigaciones Metabólicas in Buenos…
FDA Issues Safety Alerts for Bisphosphonates & SGLT2 Inhibitors
Safety The Food and Drug Administration (FDA) has updated the Warnings and Precautions sections of prescribing information for the bisphosphonate agents, including risedronate sodium tablets and combinations with calcium (Actonel/Atelvia), alendronate and combinations with vitamin D (Binosto/Fosamax), ibandronate (Boniva), etidronate (Didronel) and the RANK-ligand inhibitor denosumab (Prolia/Xgeva).1 This information relates to an increased risk for…
Progress Made in Search for a Fibromyalgia Biomarker
Fibromyalgia syndrome (FMS), rheumatoid arthritis (RA) and spondyloarthritis (SpA) all exhibit multifaceted manifestations, and many patients exhibit overlapping comorbidities. However, patients with FMS are distinct from others in that they experience widespread pain, fatigue and mood changes, including anxiety and depression. Although its hallmark symptom of pain causes rheumatologists to consider FMS a pain disorder,…
Health Data Breaches on the Rise
Large-scale health data breaches reported by doctors and health plans have been rising steadily, a new report shows. From 2010 to 2013, nearly 1000 large breaches affected more than 29 million individual health records, and more than half resulted from theft or loss of laptops, thumb drives and paper records, according to researchers with access…
Listen Now: Remembering Medicine’s Past
Collector Donah Zack Crawford talks about early surgical instruments, medical techniques, and leeches too!
Atherosclerosis Insights May Shed Light on Lupus
New research compares pathogenic immune response in SLE with immune response that contributes to atherosclerotic plaque
The ACR Recommends Cautious Approach as Biosimilars Enter U.S. Market
With the U.S. FDA’s first approval of a biosimilar drug earlier this month, rheumatologists stress the need to ensure safety, efficacy of such drugs in treating rheumatic diseases
- « Previous Page
- 1
- …
- 301
- 302
- 303
- 304
- 305
- …
- 319
- Next Page »